Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer

DOI: 10.1080/2162402X.2018.1466768

Keywords: Tumor mutational burden (TMB), Human epidermal growth factor receptor 2 (HER2), Metastatic breast cancer (MBC), Long survival outcomes, whole exome sequencing (WES)

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text